TABLE 5.
Mutations conferring LZD or DMD resistance among clinical XDR-TB isolates
| Drug | Locus | Amino acid substitution | MIC (mg/liter) | No. of isolates (%)a |
|---|---|---|---|---|
| LZD | rplC | Cys154Arg | 4–16 | 2 (40.0) |
| DMD | fbiC | Val318Ile | 32 | 2 (50.0) |
The proportion represents the rate of isolates with mutation among all resistant isolates.